Articles Tagged With:
-
More Teens Using Contraception, Data Show
While more relying on IUDs and other methods, pill use remains common
-
Troubling Trend Emerges From CTE Study
Researchers discover alarming rates of degenerative disorder in brains of deceased football players.
-
Commission Calls for Simple Lifestyle Interventions to Reduce Dementia
In a sweeping report, international experts argue targeted global health initiatives could prevent more than one-third of dementia cases.
-
Sudden Onset Headache
This article will outline the presentation of sudden onset headache in the ED, with a focus on important history and physical examination findings, associated differential diagnoses, and the appropriate workup and treatment of each condition.
-
Fungus Among Us? Dermatophyte Infections, Mimickers, and Treatment Options
Tinea refers to a superficial fungal infection of the skin, hair, and nails caused by dermatophytes, which are filamentous fungi. Trichophyton rubrum is the most common cause of dermatophyte infection, accounting for nearly 70% of infections worldwide. These infections are extremely common, but are more prominent in warm, tropical climates. Tinea is seen more commonly in black and Asian patients, has a predilection for young adults, and is three to four times more common in males.
-
Infectious Disease Alert Updates
How Dirty Is That Sandbox?; Rebuilding the Pyramids; Resistant TB in India: Unrecognized Mutations
-
GASP! Increasing Worldwide Antibiotic Resistance in Neisseria gonorrhoeae
Antibiotic-resistant gonorrhea threatens to make the infection untreatable in some patients.
-
Genital HPV in Men: How Common Is It?
In this U.S. cross-sectional survey, the prevalence of genital human papillomavirus (HPV) infection in adult men was 45%, of which 25% were high-risk subtypes. The overall rate of HPV vaccination among those who were eligible was 11%.
-
Azithromycin for Chronic Persistent Asthma
Azithromycin reduced exacerbations and improved quality of life in patients with chronic persistent asthma.
-
Tetracycline for Multiple Sclerosis?
One hundred forty-two patients within 180 days of their first demyelinating event were randomized to minocycline 100 mg BID vs. placebo. The unadjusted risk of conversion to multiple sclerosis within six months after randomization was 61.0% in the placebo group and 33.4% in the minocycline group. At 24 months, the effect of minocycline was not statistically significant.